Sanara MedTech Inc. (SMTI)

31,42 -1,70 (-5,13%) Börsenschluss: 04:00PM EDT

Sanara MedTech Inc.

1200 Summit Avenue
Suite 414
Fort Worth, TX 76102
United States
817 529 2300
https://sanaramedtech.com

Sektor(en): Healthcare
Branche: Medical Instruments & Supplies
Vollzeitmitarbeiter: 107

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Ronald T. Nixon	Executive Chairman	100k	N/A	1956
Mr. Zachary B. Fleming	Chief Executive Officer	547,6k	N/A	1975
Mr. Michael D. McNeil	CFO & Corporate Secretary	331,1k	N/A	1965
Mr. Jacob A. Waldrop	Chief Operating Officer	N/A	N/A	N/A
Mr. Bill Fitzgerald	Chief Compliance Officer	N/A	N/A	N/A
Ms. Tricia Matteson	Vice President of Marketing	N/A	N/A	N/A
Mr. Tyler Palmer	Chief Corporate Development & Strategy Officer	N/A	N/A	N/A
Dr. Christopher A. Morrison FACHM, FAPWCA, FCCWS, M.D.	President of Telehealth Services	156k	N/A	1970
Dr. Rebecca Erin Mcmahon	President of Research & Development	N/A	N/A	1985
Mr. Seth Yon	President of Commercial	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Corporate Governance

Sanara MedTech Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 9, Vorstand: 8, Shareholderrechte: 3, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.